Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BCMA”

418 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 418 results

Very early researchLooking for participantsNCT06045091
What this trial is testing

To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

Who this might be right for
Multiple MyelomaPlasma Cell Leukemia
Hrain Biotechnology Co., Ltd. 18
Not applicableLooking for participantsNCT06745687
What this trial is testing

BCMA/CD3 BsAb in the Treatment of High-risk Smoldering Multiple Myeloma

Who this might be right for
High Risk Smoldering Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 20
Testing effectiveness (Phase 2)UnknownNCT04714593
What this trial is testing

Targeting CD19 and CD22 CAR-T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia

Who this might be right for
Acute Lymphocytic Leukemia， B-Cell
Shanxi Province Cancer Hospital 24
Not applicableUnknownNCT03380039
What this trial is testing

Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma

Who this might be right for
Refractory or Relapsed Multiple Myeloma
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 6
Testing effectiveness (Phase 2)Study completedNCT04083534
What this trial is testing

First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)

Who this might be right for
Relapsed Multiple MyelomaRefractory Multiple Myeloma
Regeneron Pharmaceuticals 43
Very early researchTemporarily pausedNCT07604792
What this trial is testing

FIT-(BCMA+CD19)-CAR-T Cells in Recurrent/Refractory Autoimmune Diseases Patients.

Who this might be right for
Autoimmune Diseases
Beijing Boren Hospital 9
Early research (Phase 1)Study completedNCT03338972
What this trial is testing

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Fred Hutchinson Cancer Center 28
Early research (Phase 1)Looking for participantsNCT07715136
What this trial is testing

BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy

Who this might be right for
Inflammatory Myopathy
iCell Gene Therapeutics 10
Very early researchLooking for participantsNCT07249073
What this trial is testing

CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 9
Large-scale testing (Phase 3)Looking for participantsNCT07258511
What this trial is testing

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 400
Very early researchUnknownNCT03559764
What this trial is testing

Study of BCMA CAR-T in Multiple Myeloma

Who this might be right for
Relapsed and Refractory Multiple Myeloma
Allife Medical Science and Technology Co., Ltd. 20
Early research (Phase 1)Study completedNCT03602612
What this trial is testing

T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

Who this might be right for
Myeloma-MultipleMyeloma, Plasma-Cell
National Cancer Institute (NCI) 35
Testing effectiveness (Phase 2)Study completedNCT03548207
What this trial is testing

JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 126
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07729826
What this trial is testing

C-CAR168 CAR T-Cell Therapy for the Treatment of Lupus Nephritis Refractory to Standard Therapy

Who this might be right for
Lupus Nephritis (LN)Systemic Lupus Erythematosus (SLE)Autoimmune Diseases
AbelZeta Inc. 50
Early research (Phase 1)UnknownNCT05201118
What this trial is testing

A Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple Myeloma

Who this might be right for
Extramedullary Multiple Myeloma
Chunrui Li 20
Not applicableNot Yet RecruitingNCT07740317
What this trial is testing

Neurocognitive Trajectories After BCMA CAR-T

Who this might be right for
Multiple Myeloma (MM)CART TherapyRefractory Multiple Myeloma (RRMM)
Wake Forest University Health Sciences 50
Very early researchUnknownNCT05263817
What this trial is testing

A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis

Who this might be right for
POEMS SyndromeAmyloidosisAutoimmune Hemolytic Anemia+1 more
Zhejiang University 75
Early research (Phase 1)Looking for participantsNCT06553898
What this trial is testing

Study of Therapeutic Efficacy of CAR-T Cell Therapy in Patients With MDR-SRNS

Who this might be right for
Multi-Drug Resistant Nephrotic SyndromeCAR-T Cell Therapy
The Children's Hospital of Zhejiang University School of Medicine 18
Early research (Phase 1)Looking for participantsNCT07073547
What this trial is testing

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

Who this might be right for
Multiple Myeloma
AstraZeneca 40
Testing effectiveness (Phase 2)Looking for participantsNCT06793449
What this trial is testing

BCMA CAR-T Versus ASCT in Transplant-eligible Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 80
Next Page